Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
'Cutting edge' nonmelanoma research branches three ways
Dallas - Activation of the immune system may prove to be an importanttherapeutic adjuvant in the treatment of nonmelanoma skin cancers in difficultto treat regions, in those that have a high potential to recur, or in individualsfor whom surgery is not possible, Russell P. Hall, III, M.D., said at theannual meeting of the American College of Mohs Micrographic Surgery andCutaneous Oncology.
Related Videos
Related Content
